Role of Glucose Metabolic Reprogramming in Breast Cancer Progression and Drug Resistance
Cancers · 28.06.2023 · 15 (13) · 3390
DOI: 10.3390/cancers15133390 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 28.06.2023. Verfasst von Pan Lei und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hubei Hongshan Laboratory, College of Biomedicine and Health, Huazhong Agricultural University, Wuhan 430070, China. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 146 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, Hubei Provincial Natural Science Foundation.
Abstract (Originalsprache)
The involvement of glucose metabolic reprogramming in breast cancer progression, metastasis, and therapy resistance has been increasingly appreciated. Studies in recent years have revealed molecular mechanisms by which glucose metabolic reprogramming regulates breast cancer. To date, despite a few metabolism-based drugs being tested in or en route to clinical trials, no drugs targeting glucose metabolism pathways have yet been approved to treat breast cancer. Here, we review the roles and mechanisms of action of glucose metabolic reprogramming in breast cancer progression and drug resistance. In addition, we summarize the currently available metabolic inhibitors targeting glucose metabolism and discuss the challenges and opportunities in targeting this pathway for breast cancer treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hubei Hongshan Laboratory, College of Biomedicine and Health, Huazhong Agricultural University, Wuhan 430070, China.
- Hubei Key Laboratory of Embryonic Stem Cell Research, School of Basic Medical Sciences, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, China.
- Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- College of Life Science and Technology, Huazhong Agricultural University, Wuhan 430070, China.
- Shenzhen Institute of Nutrition and Health, Huazhong Agricultural University, Shenzhen 518000, China.
ORCID-Profile: Pan Lei, Wenzhou Wang, Fan Yao, Li Ma
Förderung
- NCI NIH HHS
- NIH HHS
- Hubei Provincial Natural Science Foundation
- Major Project of Hubei Hongshan Laboratory
- HZAU-AGIS Cooperation Fund
- Health Commission of Hubei Province
- US National Institutes of Health (NIH)
- Cancer Prevention and Research Institute of Texas (CPRIT)
Zitieren
APA
Lei, P., Wang, W., Sheldon, M., Sun, Y., Yao, F., & Ma, L. (2023). Role of Glucose Metabolic Reprogramming in Breast Cancer Progression and Drug Resistance. Cancers, 15(13), 3390. https://doi.org/10.3390/cancers15133390
Vancouver
Lei P, Wang W, Sheldon M, Sun Y, Yao F, Ma L. Role of Glucose Metabolic Reprogramming in Breast Cancer Progression and Drug Resistance. Cancers. 2023;15(13):3390. doi:10.3390/cancers15133390
BibTeX
@article{Lei2023,
author = {Lei, Pan and Wang, Wenzhou and Sheldon, Marisela and Sun, Yutong and Yao, Fan and Ma, Li},
title = {Role of Glucose Metabolic Reprogramming in Breast Cancer Progression and Drug Resistance},
journal = {Cancers},
year = {2023},
volume = {15},
number = {13},
pages = {3390},
doi = {10.3390/cancers15133390}
}
EUVIMED